Inhibition of NMDA receptors through a membrane-to-channel path

dc.contributor.author
Wilcox, Madeleine R.
dc.contributor.author
Nigam, Aparma
dc.contributor.author
Glasgow, Nathan G.
dc.contributor.author
Narangoda, Chamali
dc.contributor.author
Phillips, Matthew B.
dc.contributor.author
Patel, Dhilon S.
dc.contributor.author
Mesbahi-Vasey, Samaneh
dc.contributor.author
Turcu, Andreea L.
dc.contributor.author
Vázquez Cruz, Santiago
dc.contributor.author
Kurnikova, Maria G.
dc.contributor.author
Johnson, Jon W.
dc.date.issued
2023-02-23T12:26:57Z
dc.date.issued
2023-02-23T12:26:57Z
dc.date.issued
2022-07-15
dc.date.issued
2023-02-23T12:26:57Z
dc.identifier
2041-1723
dc.identifier
https://hdl.handle.net/2445/194025
dc.identifier
725165
dc.description.abstract
N-methyl-D-aspartate receptors (NMDARs) are transmembrane proteins that are activated by the neurotransmitter glutamate and are found at most excitatory vertebrate synapses. NMDAR channel blockers, an antagonist class of broad pharmacological and clinical significance, inhibit by occluding the NMDAR ion channel. A vast literature demonstrates that NMDAR channel blockers, including MK-801, phencyclidine, ketamine, and the Alzheimer's disease drug memantine, can bind and unbind only when the NMDAR channel is open. Here we use electrophysiological recordings from transfected tsA201 cells and cultured neurons, NMDAR structural modeling, and custom-synthesized compounds to show that NMDAR channel blockers can enter the channel through two routes: the well-known hydrophilic path from extracellular solution to channel through the open channel gate, and also a hydrophobic path from plasma membrane to channel through a gated fenestration ('membrane-to-channel inhibition' (MCI)). Our demonstration that ligand-gated channels are subject to MCI, as are voltage-gated channels, highlights the broad expression of this inhibitory mechanism.
dc.format
application/pdf
dc.format
application/pdf
dc.language
eng
dc.publisher
Nature Publishing Group
dc.relation
Reproducció del document publicat a: https://doi.org/10.1038/s41467-022-31817-z
dc.relation
Nature Communications, 2022, vol. 13, p. 4114
dc.relation
https://doi.org/10.1038/s41467-022-31817-z
dc.rights
cc-by (c) Wilcox, Madeleine R. et al., 2022
dc.rights
https://creativecommons.org/licenses/by/4.0/
dc.rights
info:eu-repo/semantics/openAccess
dc.source
Articles publicats en revistes (Farmacologia, Toxicologia i Química Terapèutica)
dc.subject
Química farmacèutica
dc.subject
Malalties neurodegeneratives
dc.subject
Pharmaceutical chemistry
dc.subject
Neurodegenerative Diseases
dc.title
Inhibition of NMDA receptors through a membrane-to-channel path
dc.type
info:eu-repo/semantics/article
dc.type
info:eu-repo/semantics/publishedVersion


Ficheros en el ítem

FicherosTamañoFormatoVer

No hay ficheros asociados a este ítem.

Este ítem aparece en la(s) siguiente(s) colección(ones)